Content Reviewed By
Reviewed by a board-certified physician (Medical) · Reviewed by a licensed attorney specializing in mass tort litigation (Legal)
If Depo-Provera Gave You a Brain Tumor, You Deserve Answers — and Compensation.
Medically reviewed by licensed healthcare professionals · Legally reviewed by mass tort litigation specialists · Last updated:
3,099+ Cases Filed in MDL 3140
Thousands of women diagnosed with meningioma — a brain tumor — after using Depo-Provera are now filing claims against Pfizer. A free, confidential evaluation takes 2 minutes.
Free. No obligation. Takes 2 minutes.
in MDL 3140
(BMJ Study)
on Market
Added 2025
How It Works
Tell Us What Happened
Answer 3 quick questions about your Depo-Provera use and diagnosis. Takes 2 minutes. No obligation.
Free Attorney Review
A mass tort attorney in our network reviews your case within 24 hours — at absolutely no cost to you.
Get the Help You Deserve
If you qualify, you're connected with an experienced attorney. No upfront fees. Attorneys only get paid if you win.
What Is the Depo-Provera Meningioma Lawsuit?
Thousands of women across the United States are filing lawsuits against Pfizer, the manufacturer of Depo-Provera, alleging that long-term use of the injectable contraceptive caused them to develop meningioma brain tumors — and that Pfizer knew about the risk but failed to adequately warn patients and doctors.
Depo-Provera (medroxyprogesterone acetate) is a hormonal birth control injection administered every three months. It has been on the market since 1992 and has been used by an estimated 24 million women in the United States.
In 2024, a landmark study published in the British Medical Journal (BMJ) found that women who used injectable medroxyprogesterone for one year or longer had a 5.6 times greater risk of developing intracranial meningiomas compared to women who never used the drug.
In response to mounting evidence, the FDA added a meningioma warning to the Depo-Provera label in December 2025 — more than 30 years after the drug was first approved. Plaintiffs argue this warning came decades too late.
Key Facts at a Glance
- MDL 3140 — Northern District of Florida, Judge M. Casey Rodgers
- 3,099+ cases filed as of April 2026, growing ~47% per month
- 5.6x increased risk of meningioma after 1+ year of use (BMJ study)
- FDA warning added December 2025 — plaintiffs say decades too late
- Defendant: Pfizer Inc. — manufacturer of Depo-Provera
- First bellwether trial: December 2026
- 24 million+ women have used Depo-Provera in the US
What Is a Meningioma?
A meningioma is a tumor that develops in the meninges — the layers of tissue that surround and protect your brain and spinal cord. While meningiomas are technically classified as non-cancerous (benign) in most cases, the word "benign" is misleading. These tumors can cause serious, life-altering symptoms depending on their size and location:
- Chronic headaches that worsen over time
- Vision changes or loss — blurred vision, double vision, or partial blindness
- Hearing loss or ringing in the ears
- Cognitive impairment — memory problems, difficulty concentrating, personality changes
- Seizures
- Weakness or numbness in the arms or legs
- Speech difficulties
Many meningiomas require neurosurgery to remove — a procedure that carries its own significant risks including infection, bleeding, stroke, and neurological damage. Some tumors are inoperable due to their location, requiring ongoing monitoring and management with radiation therapy.
For many women, a meningioma diagnosis means years of medical treatment, lost wages, diminished quality of life, and ongoing fear of tumor recurrence.
Learn More About Meningioma →Do You Qualify for a Depo-Provera Lawsuit?
You may be eligible to file a claim if all of the following apply to you:
Eligibility Criteria
- You received two or more Depo-Provera or generic medroxyprogesterone acetate injections
- You were diagnosed with a meningioma brain tumor (confirmed by MRI, CT scan, or biopsy)
- You are within your state's statute of limitations (varies by state — typically 2-3 years from diagnosis or discovery)
- You have not already retained a law firm for this specific claim
Important: If you used generic medroxyprogesterone acetate instead of brand-name Depo-Provera, you may still qualify. The active ingredient is the same regardless of whether you received the brand-name or generic version.
Not Sure If You Qualify?
Answer three quick questions to find out if you may be eligible for a Depo-Provera meningioma claim. Free. Confidential. No obligation.
Check My Eligibility →The Science: How Depo-Provera Causes Meningiomas
The link between hormonal contraceptives and meningiomas has been studied for decades, but the connection to injectable medroxyprogesterone specifically became impossible to ignore after the 2024 BMJ study.
Here's what the science shows:
The BMJ Study (2024)
Published in the British Medical Journal, this large-scale study analyzed health records of women in France who used various forms of hormonal contraception. The findings were striking:
- Women who used injectable medroxyprogesterone for 1+ year had a 5.6x greater risk of developing intracranial meningiomas
- The risk was dose-dependent — longer use correlated with higher risk
- The risk was specific to medroxyprogesterone, not all hormonal contraceptives
The Biological Mechanism
Meningiomas are known to express progesterone receptors. Medroxyprogesterone acetate — the synthetic progestin in Depo-Provera — binds to these receptors and may stimulate tumor growth. Unlike oral contraceptives that are metabolized daily, injectable medroxyprogesterone creates a sustained, elevated level of the hormone for three months per injection, creating prolonged receptor stimulation.
The FDA Response
In December 2025, the FDA required Pfizer to add a meningioma warning to the Depo-Provera label. Plaintiffs argue this warning came more than 30 years too late — and that Pfizer had access to the underlying scientific data long before the BMJ study was published.
What Is MDL 3140?
All federal Depo-Provera meningioma lawsuits have been consolidated into Multidistrict Litigation No. 3140 (MDL 3140) in the Northern District of Florida, before Judge M. Casey Rodgers.
As of April 2026:
- 3,099+ cases are pending in the MDL
- Case count is growing approximately 47% per month
- The first bellwether trial is scheduled for December 2026
- Pfizer has not yet offered a global settlement
A bellwether trial is a test case used to gauge how juries respond to the evidence. The outcome of the December 2026 trial will significantly influence whether Pfizer moves toward settlement negotiations and at what values.
Follow MDL 3140 Updates →What Compensation Could You Receive?
No settlements have been reached yet in MDL 3140, so there are no confirmed settlement amounts. However, based on the severity of meningioma injuries and comparable mass tort litigations, potential compensation may include:
- Medical expenses — past and future treatment costs, including neurosurgery, radiation, imaging, and follow-up care
- Lost wages — income lost during treatment and recovery
- Pain and suffering — physical pain, emotional distress, and diminished quality of life
- Loss of consortium — impact on family and marital relationships
Cases involving neurosurgery, multiple meningiomas, or significant neurological impairment are expected to be valued at the higher end of any future settlement tiers.
How to File a Depo-Provera Claim
If you believe you qualify, taking action involves three steps:
Step 1: Gather Your Records
Collect documentation of your Depo-Provera or medroxyprogesterone injection history (pharmacy records, insurance claims, or doctor's records) and your meningioma diagnosis (MRI reports, pathology reports, surgical records).
Step 2: Check Your State's Deadline
Every state has a statute of limitations — a legal deadline after which you can no longer file. Most states allow 2-3 years from diagnosis or discovery of the connection. Check your state's specific deadline.
Step 3: Submit a Free Case Evaluation
Share your information with attorneys experienced in Depo-Provera litigation for a free, no-obligation review of your potential claim. There is no cost to you — attorneys in these cases work on contingency, meaning they only get paid if you receive compensation.
Ready to Find Out If You Have a Claim?
Thousands of women are taking action. It costs nothing to find out if you qualify.
Start Your Free Case Review →Frequently Asked Questions
Research & Sources
The information on this page is grounded in peer-reviewed research, FDA communications, and publicly available litigation data. Key sources include:
- Peyre M, et al. (2024). "Medroxyprogesterone acetate use and risk of intracranial meningioma: national case-control study." BMJ, 384: e078078. doi: 10.1136/bmj-2023-078078. Finding: 5.6-fold increased meningioma risk after ≥1 year of medroxyprogesterone use.
- U.S. Food and Drug Administration. (August 2024). "FDA warns about rare but serious risk of brain tumor with Depo-Provera and medroxyprogesterone acetate injectable products." FDA Safety Communication. fda.gov. Finding: FDA added boxed (black box) warning for meningioma risk.
- FDA FAERS Database. (2024). Adverse Event Reporting System data for medroxyprogesterone acetate injectable products — meningioma reports: 1,990 adverse event reports on file. FDA FAERS Public Dashboard.
- PACER / Court Records. (April 2026). MDL 3140 — In re: Depo-Provera (Medroxyprogesterone Acetate) Products Liability Litigation, N.D. Fla. Case count: 3,099+ as of April 2026.
This page is for educational purposes only and does not constitute legal or medical advice. Citations are provided for informational transparency. Consult a physician for medical concerns and a licensed attorney for legal advice.
Depo-Provera Lawsuit Information by State
Each state has different filing deadlines and procedures. Find information specific to your state.